Immunologic Signatures of SARS-CoV-2 Vaccination and Disease

  • Funded by National Institutes of Health (NIH)
  • Total publications:8 publications

Grant number: 1U01CA260476-01

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $1,477,970
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    Dan H Barouch
  • Research Location

    United States of America
  • Lead Research Institution

    Beth Israel Deaconess Medical Center
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Abstract: The development of a SARS-CoV-2 vaccine may be critical to ending the COVID-19 pandemic. However, acritical gap in knowledge is the lack of understanding of correlates of SARS-CoV-2 immunity in humans.Our preliminary data suggest that antibodies correlate with protection following vaccination in nonhumanprimates and that unique antibody functional profiles appear to predict disease outcome in natural infection inhumans. Our data also point to a converging antibody profile, including both the antigen-binding domain drivingneutralization and Fc-mediated effector functions driving protective immunity. Another gap in knowledge is theunknown durability of protective immunity following SARS-CoV-2 infection and vaccination in humans.Our preliminary data suggest that antibody titers may wane quickly following SARS-CoV-2 infection in humans,but larger studies and longer follow-up are needed to define the kinetics of antibody responses in convalescentindividuals. Moreover, the durability of vaccine-elicited antibody responses remains to be determined.We hypothesize that both convalescent and vaccinated humans will develop the functional antibodysignature that correlates with vaccine protection against SARS-CoV-2 challenge in rhesus macaques.We further hypothesize that vaccination will induce antibodies with greater durability than those inducedby natural infection and that an immunologic correlate of durability can be defined.Specific Aim 1. Define the antibody profiles following SARS-CoV-2 infection or vaccination that correlatewith protection. We will dissect the functional antibody responses elicited in SARS-CoV-2 infected individualsand in SARS-CoV-2 vaccinated individuals to provide insight into correlates of protection.Specific Aim 2. Define the immunologic correlates of durability of SARS-CoV-2 antibody responsesfollowing infection or vaccination. We will compare the durability of antibody responses induced in SARS-CoV-2 infected and vaccinated individuals, and we will define an immunologic correlate of durability.

Publicationslinked via Europe PMC

Humoral profiling of pediatric patients with cancer reveals robust immunity following anti-SARS-CoV-2 vaccination superior to natural infection.

Relationship between Anti-Spike Antibodies and Risk of SARS-CoV-2 Infection in Infants Born to COVID-19 Vaccinated Mothers.

Altered Maternal Antibody Profiles in Women With Human Immunodeficiency Virus Drive Changes in Transplacental Antibody Transfer.

Functional Compartmentalization of Antibodies in the Central Nervous System During Chronic HIV Infection.

Maternal immune response and placental antibody transfer after COVID-19 vaccination across trimester and platforms.

Trends in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Seroprevalence in Massachusetts Estimated from Newborn Screening Specimens.

SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort.

Durability and Cross-Reactivity of SARS-CoV-2 mRNA Vaccine in Adolescent Children.